中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
28期
62-64,68
,共4页
支原体肺炎%儿童%阿奇霉素%氨溴索
支原體肺炎%兒童%阿奇黴素%氨溴索
지원체폐염%인동%아기매소%안추색
Mycoplasma pneumonia%Children%Azithromycin%Ambroxol
目的：探讨氨溴索联合阿奇霉素治疗儿童支原体肺炎的临床效果，并分析其对肺功能的影响。方法随机选择宁波市第六医院2013年1月~2014年4月收治的196例儿童支原体肺炎患者，根据治疗方法将所有患儿分为干预组和对照组，对照组患儿95例，在常规治疗基础上应用阿奇霉素治疗；干预组101例，应用氨溴索联合阿奇霉素治疗。观察1个疗程后的治疗效果和肺功能指标如用力肺活量(FVC)、第1秒最大呼气量(FEV1)、最高呼气流速(PEF)、用力呼气25%流速(MEF25)、用力呼气50%流速(MEF50)的变化；并观察治疗期间患儿主要症状或体征消失时间以及不良反应等结果。结果干预组患儿总有效率为96.05%(96/101)，高于对照组[86.32%(82/95)]，差异有统计学意义(P<0.05)；干预组患儿无效率为4.95%(5/101)，低于对照组[13.68%(13/95)]，差异有统计学意义(P<0.05)；干预组FVC、FEV1、PEF、MEF25和MEF50分别为(88.31±6.16)%、(84.14±5.32)%、(85.29±6.02)%、(71.36±4.62)%和(69.28±4.16)%，均高于对照组[(82.19±5.22)%、(80.31±4.94)%、(81.43±4.17)%、(64.08±3.88)%、(63.10±3.91)%]，差异均有统计学意义(P<0.05)。干预组咳喘消失时间、肺部炎症吸收、肺部啰音消失时间和治疗时间分别为(2.31±0.72)、(6.04±2.11)、(5.94±1.68)、(7.96±1.38)d，均低于对照组[(6.05±0.76)、(8.51±2.08)、(8.26±2.06)、(9.32±2.75)d]，差异均有统计学意义(P<0.05)。两组患儿不良反应结果比较，差异无统计学意义(P>0.05)。结论氨溴索联合阿奇霉素治疗儿童支原体肺炎临床效果较好，能够显著改善患儿肺功能，缩短患儿治疗时间。
目的：探討氨溴索聯閤阿奇黴素治療兒童支原體肺炎的臨床效果，併分析其對肺功能的影響。方法隨機選擇寧波市第六醫院2013年1月~2014年4月收治的196例兒童支原體肺炎患者，根據治療方法將所有患兒分為榦預組和對照組，對照組患兒95例，在常規治療基礎上應用阿奇黴素治療；榦預組101例，應用氨溴索聯閤阿奇黴素治療。觀察1箇療程後的治療效果和肺功能指標如用力肺活量(FVC)、第1秒最大呼氣量(FEV1)、最高呼氣流速(PEF)、用力呼氣25%流速(MEF25)、用力呼氣50%流速(MEF50)的變化；併觀察治療期間患兒主要癥狀或體徵消失時間以及不良反應等結果。結果榦預組患兒總有效率為96.05%(96/101)，高于對照組[86.32%(82/95)]，差異有統計學意義(P<0.05)；榦預組患兒無效率為4.95%(5/101)，低于對照組[13.68%(13/95)]，差異有統計學意義(P<0.05)；榦預組FVC、FEV1、PEF、MEF25和MEF50分彆為(88.31±6.16)%、(84.14±5.32)%、(85.29±6.02)%、(71.36±4.62)%和(69.28±4.16)%，均高于對照組[(82.19±5.22)%、(80.31±4.94)%、(81.43±4.17)%、(64.08±3.88)%、(63.10±3.91)%]，差異均有統計學意義(P<0.05)。榦預組咳喘消失時間、肺部炎癥吸收、肺部啰音消失時間和治療時間分彆為(2.31±0.72)、(6.04±2.11)、(5.94±1.68)、(7.96±1.38)d，均低于對照組[(6.05±0.76)、(8.51±2.08)、(8.26±2.06)、(9.32±2.75)d]，差異均有統計學意義(P<0.05)。兩組患兒不良反應結果比較，差異無統計學意義(P>0.05)。結論氨溴索聯閤阿奇黴素治療兒童支原體肺炎臨床效果較好，能夠顯著改善患兒肺功能，縮短患兒治療時間。
목적：탐토안추색연합아기매소치료인동지원체폐염적림상효과，병분석기대폐공능적영향。방법수궤선택저파시제륙의원2013년1월~2014년4월수치적196례인동지원체폐염환자，근거치료방법장소유환인분위간예조화대조조，대조조환인95례，재상규치료기출상응용아기매소치료；간예조101례，응용안추색연합아기매소치료。관찰1개료정후적치료효과화폐공능지표여용력폐활량(FVC)、제1초최대호기량(FEV1)、최고호기류속(PEF)、용력호기25%류속(MEF25)、용력호기50%류속(MEF50)적변화；병관찰치료기간환인주요증상혹체정소실시간이급불량반응등결과。결과간예조환인총유효솔위96.05%(96/101)，고우대조조[86.32%(82/95)]，차이유통계학의의(P<0.05)；간예조환인무효솔위4.95%(5/101)，저우대조조[13.68%(13/95)]，차이유통계학의의(P<0.05)；간예조FVC、FEV1、PEF、MEF25화MEF50분별위(88.31±6.16)%、(84.14±5.32)%、(85.29±6.02)%、(71.36±4.62)%화(69.28±4.16)%，균고우대조조[(82.19±5.22)%、(80.31±4.94)%、(81.43±4.17)%、(64.08±3.88)%、(63.10±3.91)%]，차이균유통계학의의(P<0.05)。간예조해천소실시간、폐부염증흡수、폐부라음소실시간화치료시간분별위(2.31±0.72)、(6.04±2.11)、(5.94±1.68)、(7.96±1.38)d，균저우대조조[(6.05±0.76)、(8.51±2.08)、(8.26±2.06)、(9.32±2.75)d]，차이균유통계학의의(P<0.05)。량조환인불량반응결과비교，차이무통계학의의(P>0.05)。결론안추색연합아기매소치료인동지원체폐염림상효과교호，능구현저개선환인폐공능，축단환인치료시간。
Objective To explore the clinical effect of Ambroxol combined with azithromycin in the treatment of the children with mycoplasma pneumonia, and to analyze its effect on lung function. Methods 196 children patients with mycoplasma pneumonia from January 2013 to April 2014 in the Sixth Hospital of Ningbo City were randomly selected, they were divided into intervention group and control group according to the treatment methods. 95 patients of the con-trol group, were treated with azithromycin on the basis of conventional therapy, 101 patients in the intervention group, were treated with Ambroxol combined with azithromycin. the therapeutic effect and lung function changes after a treat-ment course, the forced vital capacity (FVC), forced expiratory volume in one second (FEV1), peak expiratory flow rate (PEF), forced expiratory flow rate of 25% (MEF25), forced expiratory flow rate of 50% (MEF50) were observed, and the main symptoms and signs disappeared time and adverse reaction results during the treatment period were observed. Results The total effective rate of the intervention group was 96.05%(96/101), more than that of control group [86.32%(82/95)], there was significant difference statistically between two groups (P<0.05). The ineffective rate of patients in the intervention group was 4.95% (5/101), lower than that of the control group [13.68% (13/95)], there was significant difference statistically between two groups (P< 0.05). FVC, FEV1, PEF, MEF25 and MEF50 of the intervention group were (88.31±6.16) %, (84.14±5.32) %, (85.29±6.02) %, (71.36±4.62) % and (69.28±4.16) % respectively, higher than those of the control group [(82.19±5.22) %, (80.31±4.94) %, (81.43±4.17) %, (64.08±3.88) %, (63.10±3.91) %], the differences were statistically significant (P < 0.05). The cough disappeared time, lung inflammation absorption, pul-monary rales disappearance time and treatment time of the intervention group were (2.31±0.72) d, (6.04±2.11) d, (5.94±1.68) d and (7.96±1.38) d respectively, lower than those of the control group [(6.05±0.76), (8.51±2.08), (8.26±2.06), (9.32±2.75) d], the differences were statistically significan (P < 0.05). The patients' adverse reactions of two groups showed no significant difference (P>0.05). Conclusion There is a better effect of Ambroxol combined with azithromycin for treatment of mycoplasma pneumonia of children, which can improve the lung function and shorten the treatment time of patients significantly obviously.
